Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

Colorectal Cancer


  1. Anand, P., C. Sundaram, et al. (2008). "Curcumin and cancer: An “old-age” disease with an “age-old” solution." Cancer letters 267(1): 133-164.
  2. Thompson C et al. Promising targets and drugs in development for colorectal cancer. Semin Oncol. 2011 Aug;38(4):588-97.
  3. Gandini, S., M. Boniol, et al. (2011). "Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma." International Journal of Cancer 128(6): 1414-1424.
  4. Rothwell, P. M., M. Wilson, et al. (2010). "Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials." The Lancet 376(9754): 1741-1750.
  5. Benson, A. B., 3rd (2007). "Epidemiology, disease progression, and economic burden of colorectal cancer." J Manag Care Pharm 13(6 Suppl C): S5-18.
  6. Schernhammer, E. S., F. Laden, et al. (2003). "Night-Shift Work and Risk of Colorectal Cancer in the Nurses’ Health Study." Journal of the National Cancer Institute 95(11): 825-828.
  7. NCI 2011. National Cancer Institute. Genetics of Colorectal Cancer (PDQ®) Available at Accessed 11/17/2011.
  8. Bruce, W. R., M. Cirocco, et al. (2005). "A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation." Br J Cancer 93(6): 639-646.
  9. Larsson, S. C., N. Orsini, et al. (2005). "Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis." Journal of the National Cancer Institute 97(22): 1679-1687.
  10. Yuhara, H., C. Steinmaus, et al. (2011). "Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer[quest]." Am J Gastroenterol.
  11. Pendyala, S., L. M. Neff, et al. (2011). "Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis." The American Journal of Clinical Nutrition 93(2): 234-242.
  12. Drew, J. E. (2011). "Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin." Proceedings of the Nutrition Society FirstView: 1-6.
  13. Boyle, T., L. Fritschi, et al. (2011). "Long-Term Sedentary Work and the Risk of Subsite-specific Colorectal Cancer." American Journal of Epidemiology 173(10): 1183-1191.
  14. Mattar, M. C., D. Lough, et al. (2011). "Current management of inflammatory bowel disease and colorectal cancer." Gastrointest Cancer Res 4(2): 53-61.
  15. Rhodes, J. M. and B. J. Campbell (2002). "Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared." Trends in Molecular Medicine 8(1): 10-16.
  16. Terzić, J., S. Grivennikov, et al. (2010). "Inflammation and Colon Cancer." Gastroenterology 138(6): 2101-2114.e2105.
  17. Din, F. V. N., E. Theodoratou, et al. (2010). "Effect of aspirin and NSAIDs on risk and survival from colorectal cancer." Gut 59(12): 1670-1679.
  18. Barresi V et al. Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer. Arch Pathol Lab Med. 2008 Nov;132(11):1807-12.
  19. Melstrom LG et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008 Oct 15;14(20):6525-30.
  20. Yadav VR et al. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer. 2011 Jun 23. doi: 10.1002/ijc.26251. [Epub ahead of print]
  21. Bishnoi M et al. Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology. 2007;79(1):34-41. Epub 2006 Nov 30.
  22. Gupta, S. C., J. H. Kim, et al. (2011). "Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents." Exp Biol Med (Maywood) 236(6): 658-671.
  23. Aggarwal, B. B., M. E. Van Kuiken, et al. (2009). "Molecular Targets of Nutraceuticals Derived from Dietary Spices: Potential Role in Suppression of Inflammation and Tumorigenesis." Experimental Biology and Medicine 234(8): 825-849.
  24. Smith P. “Michael F. Holick, PhD, MD The Pioneer of Vitamin D Research.” Life Extension Magazine. Sept. 2010.
  25. Jenab, M., H. B. Bueno-de-Mesquita, et al. (2010). "Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study." BMJ 340.
  26. Ng, K., D. J. Sargent, et al. (2011). "Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741." Journal of Clinical Oncology 29(12): 1599-1606.
  27. Freedman, D. M., A. C. Looker, et al. (2007). "Prospective Study of Serum Vitamin D and Cancer Mortality in the United States." Journal of the National Cancer Institute 99(21): 1594-1602.
  28. Kim DH et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010a Nov;21(11):1919-30. Epub 2010 Sep 5.
  29. Boman, B. M., J. Z. Fields, et al. (2008). "How Dysregulated Colonic Crypt Dynamics Cause Stem Cell Overpopulation and Initiate Colon Cancer." Cancer Research 68(9): 3304-3313.
  30. D’Errico, I. and A. Moschetta (2008). "Nuclear receptors, intestinal architecture and colon cancer: an intriguing link." Cellular and Molecular Life Sciences 65(10): 1523-1543.
  31. Abdul Khalek, F. J., G. I. Gallicano, et al. (2010). "Colon cancer stem cells." Gastrointest Cancer Res(Suppl 1): S16-23.
  32. Patel, R., A. Ingle, et al. (2008a). "Polymeric black tea polyphenols inhibit 1,2-dimethylhydrazine induced colorectal carcinogenesis by inhibiting cell proliferation via Wnt/β-catenin pathway." Toxicology and Applied Pharmacology 227(1): 136-146.
  33. Hao, X., M. Bose, et al. (2007). "Inhibition of Intestinal Tumorigenesis in Apc Min/+ Mice by Green Tea Polyphenols (Polyphenon E) and Individual Catechins." Nutrition and cancer 59(1): 62-69.
  34. Mahmoud NN et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. genesis. 2000 May;21(5):921-7.
  35. Lin AY et al. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin Colorectal Cancer. 2011 Mar 1;10(1):63-9.
  36. Bland J. Farnesyl transferase inhibitors.2001;October 17-21, 2001.
  37. Asamoto M, Ota T, Toriyama-Baba H, et al. Mammary carcinomas induced in human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent, but responsive to d-limonene treatment. Jpn J Cancer Res. 2002 Jan;93(1):32-5.
  38. Nautiyal J et al. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal. 2011 Jul 20;6:7.
  39. Morales E et al. Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health. 2007 Jul;61(7):641-9.
  40. Wark PA et al. Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer. 2006 Jul 15;119(2):398-405.
  41. Bohanes P et al. Predictive molecular classifiers in colorectal cancer. Semin Oncol. 2011 Aug;38(4):576-87.
  42. Yan GR et al. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics. 2010 Mar;10(5):976-86.
  43. Lee JY et al. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One. 2011a;6(8):e23756. Epub 2011 Aug 17.
  44. Dougherty U et al. merican ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement Altern Med. 2011 Nov 9;11(1):111. [Epub ahead of print]
  45. Boland CR et al. Microsatellite instability in colorectal cancer. Gastroenterology. 2010 Jun;138(6):2073-2087.e3.
  46. Jin H et al. The study of effect of tea polyphenols on microsatellite instability colorectal cancer and its molecular mechanism. Int J Colorectal Dis. 2010 Dec;25(12):1407-15. Epub 2010 Aug 21.
  47. Dai GJ et al. [Anticancer effects of tea polyphenols on colorectal cancer with microsatellite instability in nude mice]. Zhong Xi Yi Jie He Xue Bao. 2008 Dec;6(12):1263-6.
  48. Jiang Z et al. The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther. 2010 Mar;9(3):558-68. Epub 2010 Feb 9.
  49. Cummings LC et al. Colorectal cancer screening: update for 2011. Semin Oncol. 2011 Aug;38(4):483-9.
  50. Winawer, S. J., A. G. Zauber, et al. (1993). "Prevention of Colorectal Cancer by Colonoscopic Polypectomy." New England Journal of Medicine 329(27): 1977-1981.
  51. Barclay, R. L., J. J. Vicari, et al. (2006). "Colonoscopic Withdrawal Times and Adenoma Detection during Screening Colonoscopy." New England Journal of Medicine 355(24): 2533-2541.
  52. Sanaka, M. R., N. Shah, et al. (2006). "Afternoon colonoscopies have higher failure rates than morning colonoscopies." Am J Gastroenterol 101(12): 2726-2730.
  53. Shah, H. A., L. F. Paszat, et al. (2007). "Factors associated with incomplete colonoscopy: a population-based study." Gastroenterology 132(7): 2297-2303.
  54. Manfredi, S., C. Piette, et al. (2008). "Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance." Endoscopy 40(5): 422-427.
  55. Rex DK et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology. 1997 Jan;112(1):17-23.
  56. Niv Y et al. Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Am J Gastroenterol. 1995 Nov;90(11):1974-7.
  57. Leman, E. S., R. E. Schoen, et al. (2008). "Evaluation of Colon Cancer–Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer." Clinical Cancer Research 14(5): 1349-1354.
  58. Leman, E. S., R. E. Schoen, et al. (2007). "Initial Analyses of Colon Cancer–Specific Antigen (CCSA)-3 and CCSA-4 as Colorectal Cancer–Associated Serum Markers." Cancer Research 67(12): 5600-5605.
  59. Walgenbach-Brunagel, G., B. Burger, et al. (2008). "The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer." Journal of Cellular Biochemistry 104(1): 286-294.
  60. Kronborg, O., M. Ugstad, et al. (2000). "Faecal calprotectin levels in a high risk population for colorectal neoplasia." Gut 46(6): 795-800.
  61. Roseth, A. G., J. Kristinsson, et al. (1993). "Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?" Scand J Gastroenterol 28(12): 1073-1076.
  62. Meucci, G., R. D'Inca, et al. (2010). "Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study." Dig Liver Dis 42(3): 191-195.
  63. Ahlquist, D. (2010). "New Test Measures DNA Methylation Levels to Predict Colon Cancer."
  64. PreGen-Plus™ Fact Sheet. Peggy Kochenbach, Kate Jennings. Available at: Accessed 12/6/2011.
  65. Crea F et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 2011 Dec;14(6):280-96. Epub 2011 Sep 28.
  66. Zeng Z, Cohen AM et al. Serosal cytologic study to determine free mesothelial penetration of intraperitoneal colon cancer. Cancer. 1992 Aug 15;70(4):737-40.
  67. Otsuka S, Inagaki M et al. [Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer]. Gan To Kagaku Ryoho. 2003 Oct;30(11):1598-601.
  68. Pawlik TM, Izzo F et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003 Nov;10(9):1059-69.
  69. Lau TN, Lo RH et al. Colorectal hepatic metastases: Role of radiofrequency ablation. Ann Acad Med Singapore. 2003 Mar;32(2):212-8.
  70. Tournigand C, Andre T et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229-37.
  71. Hahnfeldt P, Folkman J et al. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003 Feb 21;220(4):545-54.
  72. Zaniboni A, Torri V et al. Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer. An Italian survey. Tumori. 2005 Sep;91(5):383-7.
  73. Patel, B. B., D. Gupta, et al. (2010a). "Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R." Anticancer Res 30(2): 319-325.
  74. Sandur, S. K., A. Deorukhkar, et al. (2009). "Curcumin Modulates the Radiosensitivity of Colorectal Cancer Cells by Suppressing Constitutive and Inducible NF-κB Activity." International journal of radiation oncology, biology, physics 75(2): 534-542.
  75. O'Neil BH, Goldberg RM. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. Expert Opin Investig Drugs. 2003 Dec;12(12):1939-49.
  76. Jubb AM, Hurwitz HI. et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006 Jan 10;24(2):217-27.
  77. Chu, A. J., T. H. Chou, et al. (2004). "Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications." Front Biosci 9: 2697-2713.
  78. Wang, D. and R. N. DuBois (2008). "Pro-inflammatory prostaglandins and progression of colorectal cancer." Cancer letters 267(2): 197-203.
  79. Moreira, L. and A. Castells (2010). "Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention." Curr Drug Targets.
  80. Luqman, S. and J. M. Pezzuto (2010). "NFkappaB: a promising target for natural products in cancer chemoprevention." Phytother Res 24(7): 949-963.
  81. Arber, N., C. J. Eagle, et al. (2006). "Celecoxib for the Prevention of Colorectal Adenomatous Polyps." New England Journal of Medicine 355(9): 885-895.
  82. Reddy, B. S., J. M. Patlolla, et al. (2005). "Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids." Cancer Res 65(17): 8022-8027.
  83. Caldwell, B., S. Aldington, et al. (2006). "Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis." JRSM 99(3): 132-140.
  84. Bertagnolli, M. M., C. J. Eagle, et al. (2009). "Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial." Cancer Prevention Research 2(4): 310-321.
  85. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. Med Hypotheses. 2005;64(6):1208-10.
  86. Mountjoy KG, Finlay GJ, Holdaway IM. Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro. J Endocrinol Invest. 1987 Dec;10(6):553-7.
  87. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa). 2008 Oct;1(5):369-75.
  88. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011 Oct;34(10):2323-8.
  89. Tonnesen H, Knigge U, Bulow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct 29;2(8618):990-2.
  90. Kubecova, M., K. Kolostova, et al. (2011). "Cimetidine: An anticancer drug?" European Journal of Pharmaceutical Sciences 42(5): 439-444.
  91. Adams, W. J. and D. L. Morris (1994a). "Short-course cimetidine and survival with colorectal cancer." Lancet 344(8939-8940): 1768-1769.
  92. Adams, W. J., D. L. Morris, et al. (1994b). "Cimetidine preserves non-specific immune function after colonic resection for cancer." Aust N Z J Surg 64(12): 847-852.
  93. Platt D et al. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst. 1992 Mar 18;84(6):438-42.
  94. Tremblay PL et al. Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res. 2008 Jul 1;68(13):5167-76.
  95. Takahashi, H. K., T. Watanabe, et al. (2006). "Cimetidine Induces Interleukin-18 Production through H2-Agonist Activity in Monocytes." Molecular Pharmacology 70(2): 450-453.
  96. Matsumoto, S., Y. Imaeda, et al. (2002). "Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells." Br J Cancer 86(2): 161-167.
  97. Yoshimatsu, K., K. Ishibashi, et al. (2006). "[Can the survival of patients with recurrent disease after curative resection of colorectal cancer be prolonged by the administration of cimetidine?]." Gan To Kagaku Ryoho 33(12): 1730-1732.
  98. Mosolits S et al. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005 Jun;16(6):847-62. Epub 2005 Apr 13.
  99. Choudhury A et al. Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res. 2006;95:147-202.
  100. Liang W et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003 Mar;9(3):495-8.
  101. Garman, K. S., C. R. Acharya, et al. (2008). "A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities." Proceedings of the National Academy of Sciences 105(49): 19432-19437.
  102. Parkin, D. M. (2004). "International variation." Oncogene 23(38): 6329-6340.
  103. Giovannucci, E., W. C. Willett, et al. (1994). "DIETARY FACTORS AND RISK OF COLON-CANCER." Annals of Medicine 26(6): 443-452.
  104. Whitley, A. C., D. H. Sweet, et al. (2005). "THE DIETARY POLYPHENOL ELLAGIC ACID IS A POTENT INHIBITOR OF hOAT1." Drug Metabolism and Disposition 33(8): 1097-1100.
  105. Del Rio, D., G. Borges, et al. (2010). "Berry flavonoids and phenolics: bioavailability and evidence of protective effects." Br J Nutr 104 Suppl 3: S67-90.
  106. Linsalata, M., A. Orlando, et al. (2010). "Quercetin inhibits human DLD-1 colon cancer cell growth and polyamine biosynthesis." Anticancer Res 30(9): 3501-3507.
  107. Yang, C. S., H. Wang, et al. (2011). "Cancer prevention by tea: Evidence from laboratory studies." Pharmacological Research 64(2): 113-122.
  108. Sinha, R., D. E. Anderson, et al. (2003). "Cancer risk and diet in India." J Postgrad Med 49(3): 222-228.
  109. Ferrucci, L. M., C. R. Daniel, et al. (2010). "Measurement of spices and seasonings in India: opportunities for cancer epidemiology and prevention." Asian Pac J Cancer Prev 11(6): 1621-1629.
  110. Fung, T. T., F. B. Hu, et al. (2010). "The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer." The American Journal of Clinical Nutrition 92(6): 1429-1435.
  111. Meyerhardt, J. A., D. Niedzwiecki, et al. (2007). "Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer." Jama 298(7): 754-764.
  112. Na, H.-K. and S. Oliynyk (2011). "Effects of physical activity on cancer prevention." Annals of the New York Academy of Sciences 1229(1): 176-183.
  113. Morey, M. C., D. C. Snyder, et al. (2009). "Effects of Home-Based Diet and Exercise on Functional Outcomes Among Older, Overweight Long-term Cancer Survivors." JAMA: The Journal of the American Medical Association 301(18): 1883-1891.
  114. Bente K, P. (2011). "Exercise-induced myokines and their role in chronic diseases." Brain, Behavior, and Immunity 25(5): 811-816.
  115. Renehan, A. G., M. Tyson, et al. (2008). "Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies." The Lancet 371(9612): 569-578.
  116. Nock, N. L., C. L. Thompson, et al. (2008). "Associations Between Obesity and Changes in Adult BMI Over Time and Colon Cancer Risk." Obesity 16(5): 1099-1104.
  117. Cahill, L. E. and A. El-Sohemy (2010). "Haptoglobin genotype modifies the association between dietary vitamin C and serum ascorbic acid deficiency." The American Journal of Clinical Nutrition 92(6): 1494-1500.
  118. White, E., J. S. Shannon, et al. (1997). "Relationship between vitamin and calcium supplement use and colon cancer." Cancer Epidemiology Biomarkers & Prevention 6(10): 769-774.
  119. Giovannucci, E., M. J. Stampfer, et al. (1998). "Multivitamin Use, Folate, and Colon Cancer in Women in the Nurses' Health Study." Annals of Internal Medicine 129(7): 517-524.
  120. Jacobs, E., C. Connell, et al. (2001). "Multivitamin use and colon cancer mortality in the Cancer Prevention Study II cohort (United States)." Cancer Causes and Control 12(10): 927-934.
  121. Park, Y., D. Spiegelman, et al. (2010). "Intakes of vitamins A, C, and E and use of multiple vitamin supplements and risk of colon cancer: a pooled analysis of prospective cohort studies." Cancer Causes and Control 21(11): 1745-1757.
  122. Arul AB, Savarimuthu I, Alsaif MA, et al. Multivitamin and mineral supplementation in 1,2-dimethylhydrazine induced experimental colon carcinogenesis and evaluation of free radical status, antioxidant potential, and incidence of ACF. Can J Physiol Pharmacol. 2012 Jan;90(1):45-54.
  123. Hofstad, B., K. Almendingen, et al. (1998). "Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants." Digestion 59(2): 148-156.
  124. Touvier, M., D. S. M. Chan, et al. (2011). "Meta-Analyses of Vitamin D Intake, 25-Hydroxyvitamin D Status, Vitamin D Receptor Polymorphisms, and Colorectal Cancer Risk." Cancer Epidemiology Biomarkers & Prevention 20(5): 1003-1016.
  125. Alvarez-Díaz, S., N. Valle, et al. (2009). "Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells." The Journal of Clinical Investigation 119(8): 2343-2358.
  126. Cross, H. S., P. Bareis, et al. (2001). "25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis." Steroids 66(3-5): 287-292.
  127. Lappe, J. M., D. Travers-Gustafson, et al. (2007). "Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial." The American Journal of Clinical Nutrition 85(6): 1586-1591.
  128. Feskanich, D., J. Ma, et al. (2004). "Plasma Vitamin D Metabolites and Risk of Colorectal Cancer in Women." Cancer Epidemiology Biomarkers & Prevention 13(9): 1502-1508.
  129. Wei, M. Y., C. F. Garland, et al. (2008). "Vitamin D and Prevention of Colorectal Adenoma: A Meta-analysis." Cancer Epidemiology Biomarkers & Prevention 17(11): 2958-2969.
  130. Lee, J. E., H. Li, et al. (2011b). "Circulating Levels of Vitamin D and Colon and Rectal Cancer: The Physicians' Health Study and a Meta-analysis of Prospective Studies." Cancer Prevention Research 4(5): 735-743.
  131. Campbell, S., W. Stone, et al. (2003). "Development of gamma (gamma)-tocopherol as a colorectal cancer chemopreventive agent." Crit Rev Oncol Hematol 47(3): 249-259.
  132. Campbell, S., W. Stone, et al. (2006). "Comparative effects of RRR-alpha- and RRR-gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines." BMC Cancer 6(1): 13.
  133. Ju, J., S. C. Picinich, et al. (2010). "Cancer-preventive activities of tocopherols and tocotrienols." Carcinogenesis 31(4): 533-542.
  134. Jiang, Q., I. Elson-Schwab, et al. (2000). "γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells." Proceedings of the National Academy of Sciences 97(21): 11494-11499.
  135. Stone, W. L. and A. M. Papas (1997). "Tocopherols and the Etiology of Colon Cancer." Journal of the National Cancer Institute 89(14): 1006-1014.
  136. Yang, C. S., G. Lu, et al. (2010). "Inhibition of inflammation and carcinogenesis in the lung and colon by tocopherols." Annals of the New York Academy of Sciences 1203(1): 29-34.
  137. Bostick, R. M., J. D. Potter, et al. (1993). "Reduced Risk of Colon Cancer with High Intake of Vitamin E: The Iowa Women's Health Study." Cancer Research 53(18): 4230-4237.
  138. Ghadirian, P., A. Lacroix, et al. (1997). "Nutritional factors and colon carcinoma: a case-control study involving French Canadians in Montreal, Quebec, Canada." Cancer 80(5): 858-864.
  139. Kannappan, R., J. Ravindran, et al. (2010). "γ-Tocotrienol Promotes TRAIL-Induced Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase/p53–Mediated Upregulation of Death Receptors." Molecular Cancer Therapeutics 9(8): 2196-2207.
  140. Agarwal, M. K., M. L. Agarwal, et al. (2004). "Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association." Cell Cycle 3(2): 205-211.
  141. Wu, K., W. C. Willett, et al. (2002). "Calcium Intake and Risk of Colon Cancer in Women and Men." Journal of the National Cancer Institute 94(6): 437-446.
  142. Peters, U., N. Chatterjee, et al. (2004). "Calcium intake and colorectal adenoma in a US colorectal cancer early detection program." The American Journal of Clinical Nutrition 80(5): 1358-1365.
  143. Bernstein, H., C. Bernstein, et al. (2005). "Bile acids as carcinogens in human gastrointestinal cancers." Mutation Research/Reviews in Mutation Research 589(1): 47-65.
  144. Ahearn, T. U., M. L. McCullough, et al. (2011). "A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients." Cancer Res 71(2): 413-423.
  145. Fedirko, V., R. M. Bostick, et al. (2009). "Effects of Vitamin D and Calcium Supplementation on Markers of Apoptosis in Normal Colon Mucosa: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Cancer Prevention Research 2(3): 213-223.
  146. Grau, M. V., J. A. Baron, et al. (2007). "Prolonged Effect of Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial." Journal of the National Cancer Institute 99(2): 129-136.
  147. Hartman, T. J., P. S. Albert, et al. (2005). "The Association of Calcium and Vitamin D with Risk of Colorectal Adenomas." The Journal of Nutrition 135(2): 252-259.
  148. Weingarten, M. A., A. Zalmanovici, et al. (2008). "Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps." Cochrane Database Syst Rev(1): CD003548.
  149. Nelson, M. A., A.-C. Goulet, et al. (2005). "Studies into the Anticancer Effects of Selenomethionine against Human Colon Cancer." Annals of the New York Academy of Sciences 1059(1): 26-32.
  150. Al-Taie, O. H., J. Seufert, et al. (2003). "Selenium supplementation enhances low selenium levels and stimulates glutathione peroxidase activity in peripheral blood and distal colon mucosa in past and present carriers of colon adenomas." Nutr Cancer 46(2): 125-130.
  151. Mikac-Devic, M., N. Vukelic, et al. (1992). "Serum selenium level in patients with colorectal cancer." Biol Trace Elem Res 33: 87-94.
  152. Ghadirian, P., P. Maisonneuve, et al. (2000). "A case-control study of toenail selenium and cancer of the breast, colon, and prostate." Cancer Detect Prev 24(4): 305-313.
  153. Fernández-Bañares, F., E. Cabré, et al. (2002). "Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status." The American journal of gastroenterology 97(8): 2103-2108.
  154. Peters, U., N. Chatterjee, et al. (2006). "High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program." Cancer Epidemiol Biomarkers Prev 15(2): 315-320.
  155. Kiremidjian-Schumacher L et al. Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions. Biofactors. 2001;14(1-4):161-8.
  156. Connelly-Frost, A., C. Poole, et al. (2009). "Selenium, folate, and colon cancer." Nutrition and cancer 61(2): 165-178.
  157. Clark, L. C., G. F. Combs, et al. (1996). "Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin." JAMA: The Journal of the American Medical Association 276(24): 1957-1963.
  158. Rudolf, E., V. Kralova, et al. (2008). "Selenium and colon cancer--from chemoprevention to new treatment modality." Anticancer Agents Med Chem 8(6): 598-602.
  159. Fakih, M. G., L. Pendyala, et al. (2006). "A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors." Clinical Cancer Research 12(4): 1237-1244.
  160. Reid, M. E., A. J. Duffield-Lillico, et al. (2008). "The nutritional prevention of cancer: 400 mcg per day selenium treatment." Nutr Cancer 60(2): 155-163.
  161. Gibson, T. M., S. J. Weinstein, et al. (2011). "Pre- and postfortification intake of folate and risk of colorectal cancer in a large prospective cohort study in the United States." The American Journal of Clinical Nutrition 94(4): 1053-1062.
  162. Giovannucci, E., J. Chen, et al. (2003). "Methylenetetrahydrofolate Reductase, Alcohol Dehydrogenase, Diet, and Risk of Colorectal Adenomas." Cancer Epidemiology Biomarkers & Prevention 12(10): 970-979.
  163. Giovannucci, E. (2002). "Epidemiologic Studies of Folate and Colorectal Neoplasia: a Review." The Journal of Nutrition 132(8): 2350S-2355S.
  164. Galeone C et al. Coffee consumption and risk of colorectal cancer: a meta-analysis of case-control studies. Cancer Causes Control. 2010 Nov;21(11):1949-59. Epub 2010 Aug 1.
  165. Je Y et al. Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. Int J Cancer. 2009 Apr 1;124(7):1662-8.
  166. Dos Santos MD et al. tion of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. Biol Pharm Bull. 2006 Nov;29(11):2236-40.
  167. Van Dijk AE et al. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care. 2009 Jun;32(6):1023-5. Epub 2009 Mar 26.
  168. Kang NJ et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. enesis. 2011 Jun;32(6):921-8. Epub 2011 Feb 11.
  169. Fleischauer, A. T., C. Poole, et al. (2000). "Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers." The American Journal of Clinical Nutrition 72(4): 1047-1052.
  170. Milner, J. A. (2001a). "A Historical Perspective on Garlic and Cancer." The Journal of Nutrition 131(3): 1027S-1031S.
  171. Milner, J. A. (2001b). "Mechanisms by which garlic and allyl sulfur compounds suppress carcinogen bioactivation. Garlic and carcinogenesis." Adv Exp Med Biol 492: 69-81.
  172. Ngo, S. N. T., D. B. Williams, et al. (2007). "Does Garlic Reduce Risk of Colorectal Cancer? A Systematic Review." The Journal of Nutrition 137(10): 2264-2269.
  173. Tanaka, S., K. Haruma, et al. (2006). "Aged Garlic Extract Has Potential Suppressive Effect on Colorectal Adenomas in Humans." The Journal of Nutrition 136(3): 821S-826S.
  174. Shukla Y et al. Cancer preventive properties of ginger: a brief review. Food Chem Toxicol. 2007 May;45(5):683-90. Epub 2006 Nov 12.
  175. Murakami A et al. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis. 2002 May;23(5):795-802.
  176. Pan MH et al. 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. Mol Nutr Food Res. 2008 May;52(5):527-37.
  177. Nakamura Y et al. Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes. FEBS Lett. 2004 Aug 13;572(1-3):245-50.
  178. Brandin H et al. Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180. Phytother Res. 2007 Mar;21(3):239-44.
  179. Manju V et al. Chemopreventive efficacy of ginger, a naturally occurring anticarcinogen during the initiation, post-initiation stages of 1,2 dimethylhydrazine-induced colon cancer. Clin Chim Acta. 2005 Aug;358(1-2):60-7.
  180. Manju V et al. Effect of ginger on bacterial enzymes in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Eur J Cancer Prev. 2006 Oct;15(5):377-83.
  181. Zick SM et al. Phase II Study of the Effects of Ginger Root Extract on Eicosanoids in Colon Mucosa in People at Normal Risk for Colorectal Cancer. Cancer Prev Res (Phila). 2011 Nov;4(11):1929-37. Epub 2011 Oct 11.
  182. Takenaka, Y., T. Fukumori, et al. (2004). "Galectin-3 and metastasis." Glycoconj J 19(7-9): 543-549.
  183. Nakahara, S., N. Oka, et al. (2005). "On the role of galectin-3 in cancer apoptosis." Apoptosis 10(2): 267-275.
  184. Ingrassia, L., I. Camby, et al. (2006). "Anti-galectin compounds as potential anti-cancer drugs." Curr Med Chem 13(29): 3513-3527.
  185. Glinsky, V. V. and A. Raz (2009). "Modified citrus pectin anti-metastatic properties: one bullet, multiple targets." Carbohydr Res 344(14): 1788-1791.
  186. Nangia-Makker, P., V. Hogan, et al. (2002). "Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin." Journal of the National Cancer Institute 94(24): 1854-1862.
  187. Liu, H.-Y., Z.-L. Huang, et al. (2008). "Inhibitory effect of modified citrus pectin on liver metas journal of gastroenterology : WJG 14(48): 7386-7391.
  188. Irimura, T., Y. Matsushita, et al. (1991). "Increased Content of an Endogenous Lactose-binding Lectin in Human Colorectal Carcinoma Progressed to Metastatic Stages." Cancer Research 51(1): 387-393.
  189. Schoeppner, H. L., A. Raz, et al. (1995). "Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon." Cancer 75(12): 2818-2826.
  190. Ravindran, J., S. Prasad, et al. (2009). "Curcumin and Cancer Cells: How Many Ways Can Curry Kill Tumor Cells Selectively?" The AAPS Journal 11(3): 495-510.
  191. Cheng, C. Y., Y. H. Lin, et al. (2010). "Curcumin inhibits the proliferation of human hepatocellular carcinoma J5 cells by inducing endoplasmic reticulum stress and mitochondrial dysfunction." Int J Mol Med 26(5): 673-678.
  192. Patel, B. B. and A. P. Majumdar (2009). "Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview." Nutr Cancer 61(6): 842-846.
  193. Subramaniam, D., S. Ramalingam, et al. (2010). "Cancer stem cells: a novel paradigm for cancer prevention and treatment." Mini Rev Med Chem 10(5): 359-371.
  194. Yu, Y., S. S. Kanwar, et al. (2009). "Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX." Transl Oncol 2(4): 321-328.
  195. Patel BB, Sengupta R, Qazi S, et al. (2008b) “Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.” Int J Cancer 122(2):267-73.
  196. Bar-Sela, G., R. Epelbaum, et al. (2010). "Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications." Curr Med Chem 17(3): 190-197.
  197. Bachmeier, B. E., P. Killian, et al. (2010). "Novel aspects for the application of Curcumin in chemoprevention of various cancers." Front Biosci (Schol Ed) 2: 697-717.
  198. Han, Y., T. Haraguchi, et al. (2009). "Consumption of some polyphenols reduces fecal deoxycholic acid and lithocholic acid, the secondary bile acids of risk factors of colon cancer." J Agric Food Chem 57(18): 8587-8590.
  199. Wang, B. M., C. Y. Zhai, et al. (2009). "[The inhibitory effect of curcumin on the proliferation of HT-29 colonic cancer cell induced by deoxycholic acid]." Zhonghua Nei Ke Za Zhi 48(9): 760-763.
  200. Bartik, L., G. K. Whitfield, et al. (2010). "Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention." J Nutr Biochem 21(12): 1153-1161.
  201. He, Z.-Y., C.-B. Shi, et al. (2011). "Upregulation of p53 Expression in Patients with Colorectal Cancer by Administration of Curcumin." Cancer Investigation 29(3): 208-213.
  202. Anti, M., G. Marra, et al. (1992). "Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer." Gastroenterology 103(3): 883-891.
  203. Fernandez, E., L. Chatenoud, et al. (1999). "Fish consumption and cancer risk." Am J Clin Nutr 70(1): 85-90.
  204. Rao, C. V., Y. Hirose, et al. (2001). "Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids." Cancer Res 61(5): 1927-1933.
  205. Bancroft, L. K., J. R. Lupton, et al. (2003). "Dietary fish oil reduces oxidative DNA damage in rat colonocytes." Free Radic Biol Med 35(2): 149-159.
  206. Cheng, J., K. Ogawa, et al. (2003). "Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors." Cancer Lett 193(1): 17-24.
  207. Hall, M. N., J. E. Chavarro, et al. (2008). "A 22-year Prospective Study of Fish, n-3 Fatty Acid Intake, and Colorectal Cancer Risk in Men." Cancer Epidemiology Biomarkers & Prevention 17(5): 1136-1143.
  208. Kim, S., D. P. Sandler, et al. (2010e). "Intake of Polyunsaturated Fatty Acids and Distal Large Bowel Cancer Risk in Whites and African Americans." American Journal of Epidemiology 171(9): 969-979.
  209. Courtney, E., S. Matthews, et al. (2007). "Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas." International Journal of Colorectal Disease 22(7): 765-776.
  210. Satia, J. A., A. Littman, et al. (2009). "Associations of Herbal and Specialty Supplements with Lung and Colorectal Cancer Risk in the VITamins And Lifestyle Study." Cancer Epidemiology Biomarkers & Prevention 18(5): 1419-1428.
  211. Spencer, L., C. Mann, et al. (2009). "The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential." European journal of cancer (Oxford, England : 1990) 45(12): 2077-2086.
  212. Kolar, S. S. N., R. Barhoumi, et al. (2007). "Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca2+ accumulation in colonocytes." American Journal of Physiology - Gastrointestinal and Liver Physiology 293(5): G935-G943.
  213. Chapkin, R. S., J. Seo, et al. (2008). "Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine." Chemistry and Physics of Lipids 153(1): 14-23.
  214. Anti, M., F. Armelao, et al. (1994). "Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas." Gastroenterology 107(6): 1709-1718.
  215. Bartoli, G. M., P. Palozza, et al. (1993). "n-3 pufa and α-tocopherol control of tumor cell proliferation." Molecular Aspects of Medicine 14(3): 247-252.
  216. Benais-Pont, G., Y. M. Dupertuis, et al. (2006). "ω-3 Polyunsaturated fatty acids and ionizing radiation: Combined cytotoxicity on human colorectal adenocarcinoma cells." Nutrition (Burbank, Los Angeles County, Calif.) 22(9): 931-939.
  217. Dupertuis, Y. M., M. M. Meguid, et al. (2007). "Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids." Curr Opin Clin Nutr Metab Care 10(4): 427-432.
  218. Slagsvold, J. E., C. H. Pettersen, et al. (2010). "DHA alters expression of target proteins of cancer therapy in chemotherapy resistant SW620 colon cancer cells." Nutr Cancer 62(5): 611-621.
  219. Kuan, C. Y., T. H. Walker, et al. (2011). "Long-Chain Polyunsaturated Fatty Acids Promote Paclitaxel Cytotoxicity via Inhibition of the MDR1 Gene in the Human Colon Cancer Caco-2 Cell Line." J Am Coll Nutr 30(4): 265-273.
  220. Yamashita, K., A. Ougolkov, et al. (2007). "Adjuvant Immunochemotherapy with Protein-Bound Polysaccharide K for Colon Cancer in Relation to Oncogenic β-Catenin Activation." Diseases of the Colon & Rectum 50(8): 1169-1181.
  221. Sakamoto, J., S. Morita, et al. (2006). "Efficacy of adjuvant Immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials." Cancer Immunology, Immunotherapy 55(4): 404-411.
  222. Sakai T et al. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 2008 Aug;23(4):461-7.
  223. Ohwada S et al. uvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004 Mar 8;90(5):1003-10.
  224. Myzak, M. C. and R. H. Dashwood (2006a). "Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane." Curr Drug Targets 7(4): 443-452.
  225. Dashwood, R. H. and E. Ho (2007). "Dietary histone deacetylase inhibitors: From cells to mice to man." Seminars in Cancer Biology 17(5): 363-369.
  226. Myzak, M. C., W. M. Dashwood, et al. (2006b). "Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice." The FASEB Journal.
  227. Rudolf, E. and M. Červinka (2011). "Sulforaphane induces cytotoxicity and lysosome- and mitochondria-dependent cell death in colon cancer cells with deleted p53." Toxicology in Vitro 25(7): 1302-1309.
  228. Reuter, S., S. Eifes, et al. (2008). "Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells." Biochemical Pharmacology 76(11): 1340-1351.
  229. Kaminski, B., A. Weigert, et al. (2011). "Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death." Cancer Chemotherapy and Pharmacology 67(5): 1167-1178.
  230. Pappa, G., J. Strathmann, et al. (2007). "Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro." Carcinogenesis 28(7): 1471-1477.
  231. Cui, X., Y. Jin, et al. (2010). "Resveratrol suppresses colitis and colon cancer associated with colitis." Cancer Prev Res (Phila) 3(4): 549-559.
  232. Hope, C., K. Planutis, et al. (2008). "Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention." Mol Nutr Food Res 52 Suppl 1: S52-61.
  233. Nguyen, A. V., M. Martinez, et al. (2009). "Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer." Cancer Manag Res 1: 25-37.
  234. Zykova, T. A., F. Zhu, et al. (2008). "Resveratrol directly targets COX-2 to inhibit carcinogenesis." Mol Carcinog 47(10): 797-805.
  235. Wolter, F. and J. Stein (2002). "Resveratrol enhances the differentiation induced by butyrate in caco-2 colon cancer cells." J Nutr 132(7): 2082-2086.
  236. Tessitore, L., A. Davit, et al. (2000). "Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression." Carcinogenesis 21(8): 1619-1622.
  237. Sengottuvelan, M. and N. Nalini (2006). "Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development." Br J Nutr 96(1): 145-153.
  238. Schneider, Y., B. Duranton, et al. (2001). "Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis." Nutr Cancer 39(1): 102-107.
  239. Mahyar-Roemer, M., H. Kohler, et al. (2002). "Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells." BMC Cancer 2(1): 27.
  240. Vanamala, J., S. Radhakrishnan, et al. (2011). "Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach." Proteome Science 9(1): 49.
  241. Patel, K. R., V. A. Brown, et al. (2010b). "Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients." Cancer Research 70(19): 7392-7399.
  242. Santandreu, F. M., A. Valle, et al. (2011). "Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells." Cell Physiol Biochem 28(2): 219-228.
  243. Yang, C. S., P. Maliakal, et al. (2002). "INHIBITION OF CARCINOGENESIS BY TEA*." Annual Review of Pharmacology and Toxicology 42(1): 25-54.
  244. Issa, A., S. Volate, et al. (2007). "Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model." Carcinogenesis 28(9): 1978 - 1984.
  245. Kumar, N., D. Shibata, et al. (2007). "Green tea polyphenols in the prevention of colon cancer." Front Biosci 12: 2309-2315.
  246. Yang, C. S., J. D. Lambert, et al. (2007). "Tea and cancer prevention: Molecular mechanisms and human relevance." Toxicology and Applied Pharmacology 224(3): 265-273.
  247. Singh, B. N., S. Shankar, et al. (2011). "Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications." Biochem Pharmacol.
  248. Butt, M. S. and M. T. Sultan (2009). "Green tea: nature's defense against malignancies." Crit Rev Food Sci Nutr 49(5): 463-473.
  249. Dashwood, R. H., M. Xu, et al. (1999). "Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat." Proc Soc Exp Biol Med 220(4): 239-243.
  250. Sun, C., J. Yuan, et al. (2006). "Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies." Carcinogenesis 27(7): 1310 - 1315.
  251. Shimizu, M., Y. Fukutomi, et al. (2008). "Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study." Cancer Epidemiology Biomarkers & Prevention 17(11): 3020-3025.
  252. Kohno, H., T. Tanaka, et al. (2002). "Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats." International Journal of Cancer 101(5): 461-468.
  253. Volate, S. R., D. M. Davenport, et al. (2005). "Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin)." Carcinogenesis 26(8): 1450-1456.
  254. Yang, S. H., J. K. Lin, et al. (2003). "Anti-angiogenic effect of silymarin on colon cancer LoVo cell line." J Surg Res 113(1): 133-138.
  255. Sangeetha, N., S. Aranganathan, et al. (2010). "Oral supplementation of silibinin prevents colon carcinogenesis in a long term preclinical model." Eur J Pharmacol 643(1): 93-100.
  256. Hogan, F. S., N. K. Krishnegowda, et al. (2007). "Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer." J Surg Res 143(1): 58-65.
  257. Singh, R. P., M. Gu, et al. (2008). "Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis." Cancer Research 68(6): 2043-2050.
  258. Kaur, M., B. Velmurugan, et al. (2009). "Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft." Molecular Cancer Therapeutics 8(8): 2366-2374.
  259. Kauntz, H., S. Bousserouel, et al. (2011). "Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells." Apoptosis 16(10): 1042-1053.
  260. Li, L., J. Zeng, et al. (2010). "Targeting silibinin in the antiproliferative pathway." Expert Opinion on Investigational Drugs 19(2): 243-255.
  261. Muraikami A et al. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008 Oct 8;269(2):315-25. Epub 2008 May 7.
  262. Psahoulia FH et al. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis. 2007 May;28(5):1021-31. Epub 2006 Dec 5.
  263. Dihal AA et al. Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics. 2008 Jan;8(1):45-61.
  264. Gee Jm et al. Suppression of intestinal crypt cell proliferation and aberrant crypt foci by dietary quercetin in rats. Nutr Cancer. 2002;43(2):193-201.
  265. Cruz-Correa M et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1035-8. Epub 2006 Jun 6.
  266. Kim H, Seo JY, Roh KH, Lim JW, Kim KH. Suppression of NF-kappaB activation and cytokine production by N-acetyl cysteine in pancreatic acinar cells. Free Radic Biol Med. 2000 Oct 1;29(7):674-83.
  267. Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetyl cysteine. Mediators Inflamm. 2008;2008:716458.
  268. Origuchi T, Migita K, Nakashima T, et al. Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetyl cysteine. J Lab Clin Med. 2000 Nov;136(5):390-4.
  269. Estensen, R. D., M. Levy, et al. (1999). "N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps." Cancer Lett 147(1-2): 109-114.
  270. Ponz de Leon, M. and L. Roncucci (1997). "Chemoprevention of colorectal tumors: role of lactulose and of other agents." Scand J Gastroenterol Suppl 222: 72-75.